Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration.

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL Northern Clinics of Istanbul Pub Date : 2023-01-01 DOI:10.14744/nci.2022.22308
Ozlem Sahin, Aysun Boga, Gulay Karakus Hacioglu, Hatice Gulhan Sozen, Leyla Karadeniz Bilgin
{"title":"Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration.","authors":"Ozlem Sahin,&nbsp;Aysun Boga,&nbsp;Gulay Karakus Hacioglu,&nbsp;Hatice Gulhan Sozen,&nbsp;Leyla Karadeniz Bilgin","doi":"10.14744/nci.2022.22308","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>In Turkiye, the increased likelihood of survival of small premature babies has resulted in a higher incidence of retinopathy of prematurity (ROP), which causes severe visual impairment in childhood. Early diagnosis and timely and proper treatment of ROP can prevent vision loss. This paper discusses cases of ROP treated with bevacizumab.</p><p><strong>Methods: </strong>Patients treated with bevacizumab for ROP were evaluated retrospectively. Systolic and diastolic blood pressure values were recorded 1 day before and 2 weeks after bevacizumab administration. The Bayley III test, hearing test, eye examination, and neurological evaluation were performed.</p><p><strong>Results: </strong>The mean composite Bayley III test scores for cognition, language, motor, social-emotional, and adaptive domains in 10 patients who received bevacizumab for ROP were 75±10.8, 73.4±15.4, 71.2±10.2, 88±23.7, and 65.4±13.8, respectively. The mean values of the day before the injection and the values of the 14 days after the injection were compared, it was seen that there was a significant increase in systolic blood pressure values, especially at the end of 1<sup>st</sup> day and 1<sup>st</sup> week after the surgery. Neurological examination results were abnormal in 50% of the cases. Vision problems were detected in 40% of the cases. About 30% of the babies failed the hearing test.</p><p><strong>Conclusion: </strong>Caution needs attention in the care of neonates until further studies of the long-term benefits and effects of bevacizumab therapy are completed.</p>","PeriodicalId":19164,"journal":{"name":"Northern Clinics of Istanbul","volume":"10 4","pages":"470-476"},"PeriodicalIF":0.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/53/1f/NCI-10-470.PMC10500235.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Northern Clinics of Istanbul","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/nci.2022.22308","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: In Turkiye, the increased likelihood of survival of small premature babies has resulted in a higher incidence of retinopathy of prematurity (ROP), which causes severe visual impairment in childhood. Early diagnosis and timely and proper treatment of ROP can prevent vision loss. This paper discusses cases of ROP treated with bevacizumab.

Methods: Patients treated with bevacizumab for ROP were evaluated retrospectively. Systolic and diastolic blood pressure values were recorded 1 day before and 2 weeks after bevacizumab administration. The Bayley III test, hearing test, eye examination, and neurological evaluation were performed.

Results: The mean composite Bayley III test scores for cognition, language, motor, social-emotional, and adaptive domains in 10 patients who received bevacizumab for ROP were 75±10.8, 73.4±15.4, 71.2±10.2, 88±23.7, and 65.4±13.8, respectively. The mean values of the day before the injection and the values of the 14 days after the injection were compared, it was seen that there was a significant increase in systolic blood pressure values, especially at the end of 1st day and 1st week after the surgery. Neurological examination results were abnormal in 50% of the cases. Vision problems were detected in 40% of the cases. About 30% of the babies failed the hearing test.

Conclusion: Caution needs attention in the care of neonates until further studies of the long-term benefits and effects of bevacizumab therapy are completed.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
贝伐单抗玻璃体内给药后早产儿视网膜病变的评价。
目的:在土耳其,小早产儿存活率的增加导致了早产儿视网膜病变(ROP)的高发病率,这在儿童时期会导致严重的视力损害。早期诊断和及时适当的治疗可以预防视力丧失。本文讨论了用贝伐单抗治疗ROP的病例。方法:回顾性评价使用贝伐单抗治疗ROP的患者。记录贝伐单抗给药前1天和给药后2周的收缩压和舒张压值。进行Bayley III测试、听力测试、视力检查和神经学评估。结果:接受贝伐单抗治疗ROP的10例患者,认知、语言、运动、社交情绪和适应领域的Bayley III平均综合评分分别为75±10.8、73.4±15.4、71.2±10.2、88±23.7和65.4±13.8。对比注射前1天和注射后14天的平均值,可以看到收缩压值明显升高,尤其是在术后第1天和第1周结束时。50%的病例神经系统检查结果异常。在40%的病例中发现了视力问题。大约30%的婴儿没有通过听力测试。结论:在贝伐单抗治疗的长期获益和效果的进一步研究完成之前,需要注意新生儿的护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Northern Clinics of Istanbul
Northern Clinics of Istanbul MEDICINE, GENERAL & INTERNAL-
CiteScore
0.40
自引率
0.00%
发文量
48
审稿时长
10 weeks
期刊最新文献
Relationship between insight level and clinical and familial features in pediatric obsessive-compulsive disorder. Cryptococcal endocarditis of native valve in a patient with systemic lupus erythematosus. Evaluation of the effects of anakinra treatment on clinic and laboratory results in patients with COVID-19. Gastrointestinal endoscopic findings of autoimmune and autoinflammatory diseases in pediatric rheumatology patients. Normative reference values of major thoracic arterial vasculature in Turkiye.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1